Axis Direct's 'High Growth & QARP' and 'Value Ideas' strategies have beaten the BSE 500 TR index since June 2020. They recommend a BUY on HCG Limited and an EXIT from Acutaas Chemicals.
Axis Direct Strategies Outperform Benchmark, Recommends HCG Buy
Axis Direct's 'High Growth & QARP' strategy has delivered a 25.62% CAGR and 'Value Ideas' strategy a 29.89% CAGR since their inception on June 15, 2020, both outperforming the BSE 500 TR index's 20.38% CAGR. The firm uses a three-stage selection process involving fundamental analysis, forensic accounting, and valuation assessment, specifically avoiding cyclical and commodity-heavy sectors.
Reader Takeaway: Quality stock selection drives outperformance; monitor valuations on exiting positions.
What just happened
Axis Direct reported that its proprietary equity strategies, 'High Growth & QARP' and 'Value Ideas', have generated superior returns compared to the BSE 500 Total Return (TR) index since their launch in mid-2020. The firm also provided specific stock recommendations: a BUY for HCG Limited and an EXIT for Acutaas Chemicals Ltd.
Why this matters
For investors, this signifies the potential effectiveness of Axis Direct's investment methodology, which prioritizes quality, sustainable growth, and rigorous risk management through forensic accounting. The outperformance validates their approach, while specific stock calls offer actionable insights. The exit recommendation for Acutaas Chemicals highlights the importance of valuation discipline even for well-performing stocks.
The backstory
Since June 15, 2020, the 'High Growth & QARP' strategy has shown a Compound Annual Growth Rate (CAGR) of 25.62%, and the 'Value Ideas' strategy has achieved a CAGR of 29.89%. In comparison, the benchmark BSE 500 TR index delivered a CAGR of 20.38% over the same period. The firm's strategies intentionally steer clear of highly cyclical and commodity-focused sectors to achieve long-term outperformance.
What changes now
Investors following Axis Direct's strategies can take note of the continued strong performance. The recommendation to BUY HCG Limited suggests potential upside based on the firm's analysis of the healthcare company's growth drivers, including expansion plans and capacity growth. Conversely, the EXIT recommendation for Acutaas Chemicals signals a potential peak in its valuation, advising investors to de-risk their holdings.
Risks to watch
While the strategies aim to avoid cyclicality, broader macroeconomic downturns can still impact even quality stocks. Investors should monitor the valuation premiums of recommended stocks, as seen with the Acutaas Chemicals EXIT call, and ensure they align with the company's growth prospects and the firm's avoidance of volatile sectors.
Peer comparison
Axis Direct's strategies have outperformed the broad BSE 500 TR index. Specific peer performance data for these exact strategies against other asset management firms' comparable strategies is not provided in the filing. However, the CAGR figures indicate a competitive edge.
Context metrics (time-bound)
- High Growth & QARP Strategy CAGR: 25.62% (Since June 15, 2020)
- Value Ideas Strategy CAGR: 29.89% (Since June 15, 2020)
- BSE 500 TR Index CAGR: 20.38% (Since June 15, 2020)
- PE Ratio (as of June 30, 2026): High Growth & QARP (28.6), Value Ideas (28.3), BSE 500 TR (24.1)
What to track next
Investors should monitor the future performance of HCG Limited following the BUY recommendation and observe if the rationale for exiting Acutaas Chemicals plays out. Tracking the firm's adherence to its strategy of avoiding cyclical sectors during periods of economic uncertainty will also be crucial.